FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma
Lyu, N., Lin, Y., Kong, Y., Zhang, Z., Liu, L., Zheng, L., Mu, L., Wang, J., Li, X., Pan, T., Xie, Q., Liu, Y., Lin, A., Wu, P., Zhao, M.
BMJ Publishing Group
Published 2018
BMJ Publishing Group
Published 2018
| Publication Date: |
2018-01-10
|
|---|---|
| Publisher: |
BMJ Publishing Group
|
| Print ISSN: |
0017-5749
|
| Electronic ISSN: |
1468-3288
|
| Topics: |
Medicine
|
| Keywords: |
Gut
|
| Published by: |
| _version_ | 1836398742611165185 |
|---|---|
| autor | Lyu, N., Lin, Y., Kong, Y., Zhang, Z., Liu, L., Zheng, L., Mu, L., Wang, J., Li, X., Pan, T., Xie, Q., Liu, Y., Lin, A., Wu, P., Zhao, M. |
| beschreibung | We read with interest the article of recent advances in clinical practice of hepatocellular carcinoma (HCC) treatment by Bruix et al in Gut. 1 In this review, the Barcelona Clinic Liver Cancer (BCLC) Group recommended sorafenib as the standard treatment for BCLC-C stage (advanced stage) HCC. However, application of sorafenib as first treatment for advanced HCC worldwide was low according to a multiregional, large-scale, longitudinal cohort study. 2 This may be attributed to some limitations of sorafenib: low response rate, modest survival advantage, complex mechanism underlying acquired resistance and high-level heterogeneity of individual response. 3 4 Recently, evidence from an individual patient data meta-analysis of phase III randomised controlled trial showed no improvement in overall survival attributable to sorafenib for HBV-related HCC. 5 Therefore, more alternative strategies are highly required. 6 Hepatic arterial infusion (HAI) chemotherapy (HAIC) attracted more attentions in recent... |
| citation_standardnr | 6134913 |
| datenlieferant | ipn_articles |
| feed_id | 3103 |
| feed_publisher | BMJ Publishing Group |
| feed_publisher_url | http://www.bmj.com/ |
| insertion_date | 2018-01-10 |
| journaleissn | 1468-3288 |
| journalissn | 0017-5749 |
| publikationsjahr_anzeige | 2018 |
| publikationsjahr_facette | 2018 |
| publikationsjahr_intervall | 7984:2015-2019 |
| publikationsjahr_sort | 2018 |
| publisher | BMJ Publishing Group |
| quelle | Gut |
| relation | http://gut.bmj.com/cgi/content/short/67/2/395?rss=1 |
| schlagwort | Gut |
| search_space | articles |
| shingle_author_1 | Lyu, N., Lin, Y., Kong, Y., Zhang, Z., Liu, L., Zheng, L., Mu, L., Wang, J., Li, X., Pan, T., Xie, Q., Liu, Y., Lin, A., Wu, P., Zhao, M. |
| shingle_author_2 | Lyu, N., Lin, Y., Kong, Y., Zhang, Z., Liu, L., Zheng, L., Mu, L., Wang, J., Li, X., Pan, T., Xie, Q., Liu, Y., Lin, A., Wu, P., Zhao, M. |
| shingle_author_3 | Lyu, N., Lin, Y., Kong, Y., Zhang, Z., Liu, L., Zheng, L., Mu, L., Wang, J., Li, X., Pan, T., Xie, Q., Liu, Y., Lin, A., Wu, P., Zhao, M. |
| shingle_author_4 | Lyu, N., Lin, Y., Kong, Y., Zhang, Z., Liu, L., Zheng, L., Mu, L., Wang, J., Li, X., Pan, T., Xie, Q., Liu, Y., Lin, A., Wu, P., Zhao, M. |
| shingle_catch_all_1 | FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma Gut We read with interest the article of recent advances in clinical practice of hepatocellular carcinoma (HCC) treatment by Bruix et al in Gut. 1 In this review, the Barcelona Clinic Liver Cancer (BCLC) Group recommended sorafenib as the standard treatment for BCLC-C stage (advanced stage) HCC. However, application of sorafenib as first treatment for advanced HCC worldwide was low according to a multiregional, large-scale, longitudinal cohort study. 2 This may be attributed to some limitations of sorafenib: low response rate, modest survival advantage, complex mechanism underlying acquired resistance and high-level heterogeneity of individual response. 3 4 Recently, evidence from an individual patient data meta-analysis of phase III randomised controlled trial showed no improvement in overall survival attributable to sorafenib for HBV-related HCC. 5 Therefore, more alternative strategies are highly required. 6 Hepatic arterial infusion (HAI) chemotherapy (HAIC) attracted more attentions in recent... Lyu, N., Lin, Y., Kong, Y., Zhang, Z., Liu, L., Zheng, L., Mu, L., Wang, J., Li, X., Pan, T., Xie, Q., Liu, Y., Lin, A., Wu, P., Zhao, M. BMJ Publishing Group 0017-5749 00175749 1468-3288 14683288 |
| shingle_catch_all_2 | FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma Gut We read with interest the article of recent advances in clinical practice of hepatocellular carcinoma (HCC) treatment by Bruix et al in Gut. 1 In this review, the Barcelona Clinic Liver Cancer (BCLC) Group recommended sorafenib as the standard treatment for BCLC-C stage (advanced stage) HCC. However, application of sorafenib as first treatment for advanced HCC worldwide was low according to a multiregional, large-scale, longitudinal cohort study. 2 This may be attributed to some limitations of sorafenib: low response rate, modest survival advantage, complex mechanism underlying acquired resistance and high-level heterogeneity of individual response. 3 4 Recently, evidence from an individual patient data meta-analysis of phase III randomised controlled trial showed no improvement in overall survival attributable to sorafenib for HBV-related HCC. 5 Therefore, more alternative strategies are highly required. 6 Hepatic arterial infusion (HAI) chemotherapy (HAIC) attracted more attentions in recent... Lyu, N., Lin, Y., Kong, Y., Zhang, Z., Liu, L., Zheng, L., Mu, L., Wang, J., Li, X., Pan, T., Xie, Q., Liu, Y., Lin, A., Wu, P., Zhao, M. BMJ Publishing Group 0017-5749 00175749 1468-3288 14683288 |
| shingle_catch_all_3 | FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma Gut We read with interest the article of recent advances in clinical practice of hepatocellular carcinoma (HCC) treatment by Bruix et al in Gut. 1 In this review, the Barcelona Clinic Liver Cancer (BCLC) Group recommended sorafenib as the standard treatment for BCLC-C stage (advanced stage) HCC. However, application of sorafenib as first treatment for advanced HCC worldwide was low according to a multiregional, large-scale, longitudinal cohort study. 2 This may be attributed to some limitations of sorafenib: low response rate, modest survival advantage, complex mechanism underlying acquired resistance and high-level heterogeneity of individual response. 3 4 Recently, evidence from an individual patient data meta-analysis of phase III randomised controlled trial showed no improvement in overall survival attributable to sorafenib for HBV-related HCC. 5 Therefore, more alternative strategies are highly required. 6 Hepatic arterial infusion (HAI) chemotherapy (HAIC) attracted more attentions in recent... Lyu, N., Lin, Y., Kong, Y., Zhang, Z., Liu, L., Zheng, L., Mu, L., Wang, J., Li, X., Pan, T., Xie, Q., Liu, Y., Lin, A., Wu, P., Zhao, M. BMJ Publishing Group 0017-5749 00175749 1468-3288 14683288 |
| shingle_catch_all_4 | FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma Gut We read with interest the article of recent advances in clinical practice of hepatocellular carcinoma (HCC) treatment by Bruix et al in Gut. 1 In this review, the Barcelona Clinic Liver Cancer (BCLC) Group recommended sorafenib as the standard treatment for BCLC-C stage (advanced stage) HCC. However, application of sorafenib as first treatment for advanced HCC worldwide was low according to a multiregional, large-scale, longitudinal cohort study. 2 This may be attributed to some limitations of sorafenib: low response rate, modest survival advantage, complex mechanism underlying acquired resistance and high-level heterogeneity of individual response. 3 4 Recently, evidence from an individual patient data meta-analysis of phase III randomised controlled trial showed no improvement in overall survival attributable to sorafenib for HBV-related HCC. 5 Therefore, more alternative strategies are highly required. 6 Hepatic arterial infusion (HAI) chemotherapy (HAIC) attracted more attentions in recent... Lyu, N., Lin, Y., Kong, Y., Zhang, Z., Liu, L., Zheng, L., Mu, L., Wang, J., Li, X., Pan, T., Xie, Q., Liu, Y., Lin, A., Wu, P., Zhao, M. BMJ Publishing Group 0017-5749 00175749 1468-3288 14683288 |
| shingle_title_1 | FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma |
| shingle_title_2 | FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma |
| shingle_title_3 | FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma |
| shingle_title_4 | FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma |
| timestamp | 2025-06-30T23:31:55.419Z |
| titel | FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma |
| titel_suche | FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma |
| topic | WW-YZ |
| uid | ipn_articles_6134913 |